Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Empagliflozin in DMD-Associated Dilated Cardiomyopathy: NCT06643442 Clinical Landscape Report 2026
16 September 2026
NCT06643442 clinical landscape for DMD-Associated Dilated Cardiomyopathy: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
β-globin restored autologous hematopoietic stem cells (Hemogen Gene) in Beta-Thalassemia: NCT06655662 Clinical Landscape Report 2026
16 September 2026
NCT06655662 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Alrizomadlin in Mesothelioma, Malignant: NCT06654050 Clinical Landscape Report 2026
16 September 2026
NCT06654050 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tacrolimus in Muscular Dystrophy, Duchenne: NCT06692426 Clinical Landscape Report 2026
16 September 2026
NCT06692426 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tezepelumab in Severe asthma: NCT06705764 Clinical Landscape Report 2026
16 September 2026
NCT06705764 clinical landscape for Severe asthma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
β-globin restored autologous hematopoietic stem cells (Hemogen Gene) in Beta-Thalassemia: TCTR20241029003 Clinical Landscape Report 2026
16 September 2026
TCTR20241029003 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vamorolone in Muscular Dystrophy, Duchenne: NCT06713135 Clinical Landscape Report 2026
16 September 2026
NCT06713135 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[203Pb]PSV359 in Sarcoma: NCT06710756 Clinical Landscape Report 2026](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_06_34c12a0757.jpg)
9 min read
[203Pb]PSV359 in Sarcoma: NCT06710756 Clinical Landscape Report 2026
16 September 2026
NCT06710756 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MT-027 in Malignant Pleural Mesothelioma: NCT06726564 Clinical Landscape Report 2026
16 September 2026
NCT06726564 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Givinostat Hydrochloride in Muscular Dystrophy, Duchenne: NCT06769633 Clinical Landscape Report 2026
16 September 2026
NCT06769633 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LNK101 in Advanced Bile Duct Carcinoma: NCT06756035 Clinical Landscape Report 2026
16 September 2026
NCT06756035 clinical landscape for Advanced Bile Duct Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
[68Ga]FAPI-46 in Malignant Pleural Mesothelioma: NCT06790082 Clinical Landscape Report 2026
16 September 2026
NCT06790082 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.